SOX9 expression and its methylation status in gastric cancer.

Virchows Archiv : an International Journal of Pathology
Minhua SunMasashi Fukayama

Abstract

SOX9 is a member of the SOX [Sry-related high-mobility group (HMG) box] family and is required for the development and differentiation of multiple cell lineages. To clarify the significance of SOX9 in gastric carcinoma (GC), immunohistochemical expression of SOX9 and the CpG island methylation status of SOX9 were evaluated and compared with clinicopathological factors including overall survival. SOX9 expression was immunohistochemically evaluated in 382 GC tumors and the methylation status was examined in 121 GC tumors. SOX9 expression and its methylation status in six GC cell lines, their Epstein-Barr virus (EBV)-infected cell lines, and two EBV-associated GC cell lines was also examined. The SOX9 expression increased from non-neoplastic mucosa to early cancer. High expression of SOX9 was seen in 212 cases (56%). SOX9 expression was inversely related to advanced tumor stage, vessel infiltration, nodal metastasis, and EBV infection. Fifty-eight (48%) of 121 GC tumors had a methylated promoter in GC and the methylated status was related to low expression. The expression and methylation status were not related to prognosis. Three of six cell lines had increased methylation through EBV infection and decreased SOX9 expression. Upre...Continue Reading

References

Apr 1, 1997·Molecular and Cellular Biology·V LefebvreB de Crombrugghe
Jul 5, 2003·Genes & Development·C Claus StoltMichael Wegner
Jul 9, 2004·Development·Brigitte MoniotPascal de Santa Barbara
Apr 29, 2005·Cell Research·In Seon Choi, Tsung Teh Wu
Mar 15, 2006·World Journal of Gastroenterology : WJG·Yao ChenZeng-Ni Yi
May 19, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Moon-Sung ChangMasashi Fukayama
Jul 13, 2007·The International Journal of Biochemistry & Cell Biology·Véronique LefebvreBhattaram Pallavi
Aug 8, 2007·Gastroenterology·Yuko Mori-AkiyamaBenoit de Crombrugghe
Mar 13, 2008·Journal of Cutaneous Pathology·Valérie P I VidalAndreas Schedl
Mar 21, 2008·Modern Rheumatology·Haruhiko Akiyama
Apr 15, 2008·BMC Gastroenterology·Hanna HaveriMarkku Heikinheimo
Jun 19, 2008·Differentiation; Research in Biological Diversity·Martin K ThomsenAmanda Swain
Jul 12, 2008·Cancer Science·Masashi FukayamaHiroshi Uozaki
Nov 21, 2008·American Journal of Clinical Pathology·Bingjian LüMaode Lai
Aug 4, 2009·The International Journal of Biochemistry & Cell Biology·C Claus Stolt, Michael Wegner
Aug 4, 2009·The International Journal of Biochemistry & Cell Biology·Francisco Barrionuevo, Gerd Scherer
Oct 13, 2009·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Do Youn ParkGregory Y Lauwers
Jan 28, 2010·Cancer Research·Martin K ThomsenUNKNOWN Transatlantic Prostate Group
Jul 24, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shih Sheng JiangI-Shou Chang
Feb 16, 2011·Experimental Biology and Medicine·Geetika ChakravartyDebasis Mondal

❮ Previous
Next ❯

Citations

Feb 28, 2013·International Journal of Molecular Sciences·Yongzhao ZhuXiaoming Liu
Jun 14, 2012·Epigenomics·Ali R JazirehiPeter B Wenn
Jul 3, 2013·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Yoo Jin ChoiWon Sang Park
Mar 17, 2016·Human Pathology·Maiken Lise Marcker EspersenEstrid Høgdall
Oct 13, 2012·Gastroenterology·Alfred S L ChengFrancis K L Chan
Jan 1, 2014·Cancer Cell International·Yinguo BaiShaoping Ji
Jun 5, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ning YangXuejun Jiang
Sep 6, 2015·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Hajime MatsushimaSusumu Eguchi
Sep 10, 2015·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Qianqian GaoXu Ma
Mar 25, 2015·Cellular Oncology (Dordrecht)·Xiaoyang XuDongqiu Dai
Dec 12, 2012·Early Human Development·Renato Nicolás HoppJacks Jorge
Apr 16, 2013·Biochimica Et Biophysica Acta·Anna PanzaAda Piepoli
Feb 9, 2018·American Journal of Human Biology : the Official Journal of the Human Biology Council·Lu WangZhan-Bing Ma
Jul 6, 2019·Disease Markers·Patrícia MesquitaRaquel Almeida
Jul 7, 2020·Frontiers in Cell and Developmental Biology·Diana PáduaPatrícia Mesquita
Dec 24, 2018·Expert Opinion on Therapeutic Targets·Estefania Carrasco-GarciaAnder Matheu
May 7, 2019·Journal of Oncology·Maribel Aguilar-MedinaCésar López-Camarillo
Nov 5, 2016·Cancer Research·Juliana Carvalho SantosAnder Matheu
Feb 2, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Munmun PandaBijesh K Biswal
Mar 5, 2021·International Journal of Biological Macromolecules·Asal Jalal AbadiMichael R Hamblin
Jan 9, 2020·Biochemical Pharmacology·Samir JanaSharad S Singhal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.